Administration of Intravenous NRX100 (Ketamine) vs Placebo Infusion for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Patients With Bipolar Depression
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Dec 2018
At a glance
- Drugs Cycloserine/lurasidone (Primary)
- Indications Bipolar depression
- Focus Registrational; Therapeutic Use
- Acronyms SevereBD
- Sponsors NeuroRX
- 29 Nov 2018 Planned End Date changed from 31 Mar 2019 to 31 Mar 2020.
- 29 Nov 2018 Planned primary completion date changed from 31 Mar 2019 to 31 Dec 2019.
- 29 Nov 2018 Planned initiation date changed from 1 May 2018 to 1 Jan 2019.